SS-31 and NAD+ for glowing skin: what the science says

What's this video probably claiming?

Based on the caption pairing SS-31 "before" NAD+ with hashtags like glowingskin, glowup, and antiaging, the creator is almost certainly positioning SS-31 peptide as a skin-enhancing compound that either primes the body for NAD+ therapy or works synergistically with it to produce visible cosmetic results. The "natural glowing skin" framing suggests the claim is that this stack produces noticeable aesthetic improvements, possibly through mitochondrial support or cellular energy optimization. Some creators in this space also imply SS-31 reduces oxidative stress in skin tissue, which then gets amplified by NAD+ precursor supplementation. That's a neat narrative. It is also almost entirely built on animal data and extrapolation from cardiac research, not dermatology trials.

What does the science actually show?

SS-31 (also called elamipretide or Bendavia) is a mitochondria-targeting tetrapeptide that works by binding to cardiolipin on the inner mitochondrial membrane. The published human clinical work has focused almost exclusively on heart failure and kidney disease. The PROGRESS-HF trial (Dauber et al., 2020, JACC Heart Failure) tested intravenous elamipretide in patients with heart failure with preserved ejection fraction and found modest improvements in left ventricular function. Skin is not the target organ in any Phase 2 or Phase 3 trial. For NAD+ specifically, Yoshino et al. (2021, Science) showed that 250 mg daily NMN supplementation raised blood NAD+ levels in postmenopausal women, but skin-specific outcomes were not measured. The idea that these two compounds together produce glowing skin is mechanistically plausible on a whiteboard and clinically unvalidated in humans.

Where does the social media noise diverge from clinical reality?

The TikTok peptide space has a pattern: take a compound with compelling mitochondrial biology, strip out the disease context, and rebrand it as a biohacking beauty tool. SS-31 is particularly vulnerable to this because its mechanism, reducing mitochondrial reactive oxygen species, sounds like exactly what skin aging is about. And oxidative stress does matter in photoaging. But the leap from "this peptide reduces ROS in cardiac cells in rats" to "this peptide gives you glowing skin" skips several layers of evidence. A 2022 review by Miwa and Brand in Aging Cell noted that mitochondrial membrane potential improvements with SS-31 have been demonstrated in muscle and cardiac tissue in rodents, with no peer-reviewed skin-specific human data. Sequencing it before NAD+ as if there is an established protocol is particularly misleading. No published clinical protocol supports this ordering for cosmetic purposes.

What should you actually know?

SS-31 is a research peptide. It is not FDA-approved for any indication, and compounded versions available through telehealth are not equivalent to the investigational drug used in clinical trials. The doses used in human cardiac studies were administered intravenously in controlled settings, not via subcutaneous self-injection at home. If you are considering peptide therapy for skin health, GHK-Cu has more dermatology-specific research behind it, including a study by Pickart and Margolina (2018, Symmetry) describing fibroblast stimulation and collagen synthesis effects, though even that evidence base is preliminary. NAD+ precursors like NMN or NR have a more developed safety profile for oral use. The SS-31 plus NAD+ stack for glowing skin is not a clinical protocol. It is content. Those are different things.